The molecular fingerprint of neuroinflammation in COVID-19: A comprehensive discussion on molecular mechanisms of neuroinflammation due to SARS-COV2 antigens. — CFSMEATLAS
The molecular fingerprint of neuroinflammation in COVID-19: A comprehensive discussion on molecular mechanisms of neuroinflammation due to SARS-COV2 antigens.
Zayeri, Zeinab Deris, Torabizadeh, Mehdi, Kargar, Masoud et al. · Behavioural brain research · 2024 · DOI
Quick Summary
This study explains how COVID-19 can damage the brain and nervous system, causing inflammation and injury. The researchers found that about half of people recovering from COVID-19 develop ME/CFS symptoms, and brain scans show reduced activity in key areas that control memory, movement, and mood. The study focuses on the biological mechanisms—essentially how viruses trigger harmful immune responses in the brain that can lead to long-term neurological problems.
Why It Matters
Understanding the neuroinflammatory mechanisms underlying post-COVID ME/CFS is critical because it provides biological validation for a condition often dismissed as psychosomatic. This work identifies specific molecular targets (microglia, cytokines, oxidative stress pathways) that could become therapeutic intervention points for ME/CFS patients who currently lack approved treatments.
Observed Findings
Approximately 50% of COVID-19 patients develop ME/CFS after recovery.
Brain imaging in long COVID shows hypometabolism in the olfactory bulbs, limbic system, brainstem, and cerebellum.
Ninety imaging and neuropathological studies documented white matter, brainstem, frontotemporal, and oculofrontal lesions in COVID-19 patients.
Microglia activation and elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) are associated with neuronal dysfunction and death.
Reactive oxygen species and impaired antioxidant defenses contribute to oxidative brain damage in COVID-19.
Inferred Conclusions
Neuroinflammation triggered by SARS-CoV-2 antigens is a key mechanism underlying both acute COVID-19 neurology and prolonged post-COVID ME/CFS symptoms.
Multiple signaling pathways (NF-κB, MAPK, IRF) converge on microglia activation, perpetuating harmful inflammatory cycles in brain tissue.
The neurological and neuropsychiatric complications of COVID-19 and long COVID deserve greater clinical and research attention as a major public health priority.
Remaining Questions
What factors determine whether an individual develops ME/CFS after COVID-19 versus recovery without neurological complications?
What This Study Does Not Prove
This is a mechanistic review, not primary research, so it does not present new experimental data proving causation between specific viral mechanisms and ME/CFS. The study correlates brain abnormalities with ME/CFS symptoms but does not definitively establish which inflammatory pathways are sufficient or necessary to cause disease. It also cannot determine whether identified lesions and inflammation are reversible or permanent.
Are the documented brain lesions and hypometabolism reversible with time or targeted treatment, or do they represent permanent damage?
Which specific inflammatory pathway (NF-κB, MAPK, or IRF) is the most promising therapeutic target for reducing neuroinflammation in post-COVID ME/CFS?
How do viral persistence, molecular mimicry, or autoimmune mechanisms contribute to sustained neuroinflammation in long COVID compared to acute infection?